At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Jun 3, 2026 at 07:19 ET
Celcuity announced a proposed $400M underwritten public offering of convertible senior notes due 2032. The offering is dilutive to existing shareholders and signals significant capital needs for a clinical-stage biotech, likely to fund pipeline development. Given the company's pre-revenue status and the large size relative to its $4.5B market cap, this is a notable but not transformative event.
- Proposed underwritten public offering of $400M aggregate principal amount of convertible senior notes due 2032.
- Celcuity is a clinical-stage biotechnology company with no approved products or disclosed revenue.
- The offering represents approximately 8.9% of the company's $4.5B market cap.
- Convertible notes will likely convert into equity, adding dilution over time.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access